CTH120 Medication Granted Orphan Designation in EU

CTH120 Medication Granted Orphan Designation in EU

307948

CTH120 Medication Granted Orphan Designation in EU

Connecta Therapeutics‘ CTH120 molecule has been granted orphan designation by the European Medicines Agency (EMA) for treating fragile X syndrome, the leading cause of hereditary intellectual disability and autism spectrum disorders. The company said it intends to begin human clinical trials as early as next year to test CTH120, which is designed to improve cognitive ability and ease the symptoms of autism. Orphan designation given by the EMA is used for medications that are intended to…

You must be logged in to read/download the full post.